In a study of women with bone metastases from breast cancer, Xgeva™ (denosumab) delayed bone complications for five months longer than Zometa® (zoledronic acid). These updated results from a Phase III clinical trial were presented at the 2010 San Antonio Breast Cancer Symposium.
Metastatic cancer refers to cancer that has spread to distant sites in the body. Several types of cancer—including breast cancer—have a tendency to spread to the bone. Bone metastases can lead to serious problems such as fracture and spinal cord compression and may require treatment with surgery or radiation therapy.
Bisphosphonate drugs such as Zometa are commonly used to reduce the risk of complications from bone metastases. Researchers continue, however, to explore new approaches to treatment.
Xgeva is a drug that targets a protein known as the RANK ligand. This protein regulates the activity of osteoclasts (cells that break down bone). Xgeva was recently approved for the prevention of bone complications such as fracture in patients with bone metastases from solid (not blood-related) cancers.
To directly compare Xgeva to Zometa among breast cancer patients with bone metastases, researchers conducted a Phase III clinical trial among more than 2,000 patients. Study participants were assigned to receive either Xgeva or Zometa. Zometa is given intravenously, and Xgeva is given as a subcutaneous (under-the-skin) injection.
The objective of the study was to determine whether the occurrence of bone complications (“skeletal related events”) differed between the two study groups. The bone complications that were evaluated were fracture, radiation to the bone, surgery to the bone, and spinal cord compression.
The results of this study suggest that Xgeva is more effective than Zometa at delaying or preventing skeletal complications in breast cancer patients with bone metastases.
Reference: Stopeck A, Martin M, Ritchie D et al. Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: results from the extended blinded treatment phase. Presented at the 33rd annual San Antonio Breast Cancer Symposium, December 8-12, 2010. Abstract P6-14-01.
Copyright © 2016 CancerConsultants. All Rights Reserved.
[ abana 60 tablet bottle $158.00 | cialis 100mg pills 360 pills $691.00 | xalatan 2.5ml eye drops bottle $139.00 | levitra versus viagra | tadalis 20mg pills $54.00 | rythmol 150mg pills $256.00 | omnicef 300mg pills $262.00 | aygestin 5mg pills $150.00 | parlodel 2.5mg pills $84.00 | keflex 250mg pills $198.00 | proscar 5mg pills $256.00 | arcoxia 90mg pills $95.00 | chloroquine 500mg pills $91.00 | aricept 10mg pills $309.00 | viagra canada generic | tenormin 50mg pills $174.00 | vigora 100mg pills $182.00 | accutane 40mg pills $219.00 | loxitane 25mg pills $262.00 | lidoderm 5% 30gm tube $43.00 | keflex 500mg pills $172.00 | cialis for less 20 mg | detrol 2mg pills $220.00 | clopidogrel 75mg pills $161.00 | viagra pill splitter | ceclor 250mg pills $135.00 | prasugrel 10mg pills $216.00 | tricor 160mg pills $140.00 | sitagliptin 25mg pills $201.00 | fluticasone 125mcg inhaler $154.00 | buy viagra | deltasone 10mg pills $122.00 | cytoxan 50mg pills $165.00 | accutane 10mg pills $117.00 | professional levitra 20mg pills $127.00 | best way to take cialis | brand viagra over the net | buying viagra in the us | sitagliptin 50mg pills $138.00 | drink alcohol with viagra | microzide 12.5mg pills $162.00 | anafranil 75mg pills $132.00 | norvasc 2.5mg pills $91.00 | allegra 120mg pills $188.00 | elavil 50mg pills $141.00 | viagra online consultation | clomipramine 75mg pills 360 pills $418.00 | allegra 180mg pills $135.00 | clopidogrel 75mg pills $161.00 | prandin 2mg pills $269.00 | lynoral 50mcg pills $127.00 | viagra dosages | keppra 1000mg pills $515.00 | what if i take too much viagra ]
© Nebraska Hematology-Oncology | Web Design & Development by UNANIMOUS